Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS Insider

The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.

06/19/2026, 5:09 AM • GlobeNewswire

ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown

Champlain Investment Partners completely exited its position in ServisFirst Bancshares, selling 1.57 million shares worth approximately $124.23 million. However, the exit appears to be part of broader fund downsizing rather than a targeted judgment on the company, as Champlain's reportable AUM contracted by roughly $2 billion quarter-over-quarter. The position represented only 1.14% of the fund's prior-quarter holdings.

05/17/2026, 4:32 PM • The Motley Fool

3 Reasons Boston Scientific Stock Could Quietly 5X as the World Ages

Boston Scientific is well-positioned to capitalize on global aging demographics, with products addressing age-related conditions like atrial fibrillation, chronic pain, and Parkinson's disease. Recent acquisitions of Penumbra and Silk Road Medical expand its stroke treatment capabilities. Despite strong fundamentals and double-digit growth, the stock has been beaten down following conservative 2026 guidance, creating a potentially attractive valuation opportunity.

03/05/2026, 1:15 PM • The Motley Fool

Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

02/02/2026, 5:49 PM • GlobeNewswire

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.

01/28/2026, 2:23 PM • Benzinga

Halper Sadeh LLC Encourages PEN, EXAS, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

01/21/2026, 4:52 PM • GlobeNewswire

Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface

Boston Scientific has issued a recall of certain AXIOS stents and electrocautery-enhanced delivery systems due to deployment and expansion difficulties. As of December 23, the company reported 167 serious injuries and 3 deaths associated with the issue. The FDA is actively reviewing the potentially high-risk device issue. The complications occur during delivery, not after implantation.

01/21/2026, 12:30 PM • Benzinga

Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights

Investor rights law firm Halper Sadeh LLC is investigating three companies for potential securities law violations and fiduciary duty breaches related to major transactions: Penumbra's $374 per share sale to Boston Scientific, Calavo's acquisition by Mission Produce for $14.85 cash plus stock, and Mission Produce's merger with Calavo. The firm is seeking increased consideration for shareholders and additional disclosures.

01/17/2026, 12:45 PM • GlobeNewswire

Deal Dispatch: From $14B Medtech Buys To Vodka Bankruptcies, This Week's M&A Roundup

This week's M&A activity spans major acquisitions and bankruptcies. Boston Scientific agreed to acquire Penumbra for $14.6 billion, expanding its neurovascular presence. Devon Energy and Coterra Energy are in merger discussions to create a major shale producer. Paramount Skydance's lawsuit against Warner Bros. Discovery was rejected by a Delaware judge. BitMine Immersion invested $200 million in MrBeast's Beast Industries. Meanwhile, spirits producers Stoli Group USA and Kentucky Owl converted their Chapter 11 bankruptcies to Chapter 7 liquidation, and Sailormen Inc., a Popeyes franchisee, filed for bankruptcy.

01/16/2026, 3:54 PM • Benzinga

Global Neurovascular Devices Market Set to Grow Steadily at a CAGR of ~8% by 2032 | DelveInsight

The global neurovascular devices market is projected to grow from USD 3.6 billion in 2024 to USD 6.8 billion by 2032, driven by increasing prevalence of neurovascular disorders, technological advancements, and growing preference for minimally invasive procedures. North America leads the market with 30% share, while Asia-Pacific emerges as a major growth driver. Key players include Johnson & Johnson, Medtronic, Stryker, and Terumo Corporation.

01/15/2026, 1:00 PM • GlobeNewswire

Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy

Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.

01/15/2026, 8:42 AM • Benzinga

Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?

Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.

01/13/2026, 1:04 PM • Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?

Multiple large-cap companies reported strong Q3 earnings and raised fiscal year guidance, leading to significant stock price gains across various sectors including technology, travel, and healthcare.

11/09/2025, 7:08 AM • Benzinga